Search

1215 Result(s)
Sort by

Annual Press Conference 2024

Annual Press Conference 2024

Boehringer Ingelheim presents the 2023 results and an outlook for 2024 at the Annual Press Conference on April 16, 2024.
Empowering smallholder farmers

Empowering smallholder farmers

The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
Niha Agarwalla

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Stroke Risk Factors Symptoms

Stroke Risk Factors Symptoms

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
Outlook for Partnering in Animal Health 2024

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Partnering in Retinal Health

Partnering in Retinal Health

Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Galym Zhunisbekov

Galym Zhunisbekov

Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, reflects on our philosophy and our impact on millions of lives.
Annual Results Press Conference 2023

Annual Results Press Conference 2023

Boehringer Ingelheim presents the 2022 results and an outlook for 2023 at the Annual Press Conference on March 29, 2023.
Phase 3 studies survodutide obesity and overweight

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Cristian Torreblanca

Cristian Torreblanca

Cristian Torreblanca Estrada is a Corporate Global Facilities and Engineering Senior Manager Controller in Germany – with plans for growth across the global business.
EMPRISE-interim-analysis

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Collaboration in Oncology

Collaboration in Oncology

Oncology is a fast-moving, challenging and complex field and only with collaboration between different disciplines, we can be able to win the fight against cancer.
Heidelberg Transforming Science Day 2025

Heidelberg Transforming Science Day 2025

The Heidelberg Transforming Science Day profiles what makes our innovation different including our ground-breaking research and our diverse pipeline.